When a patient arrives at the hospital with an infection, the key to treating them and getting them out is the speed at which they get the right antibiotics.
This is because of the time it takes to identify the infecting pathogen with real certainty before commencing treatment. Hence, to save time, doctors administer broad-spectrum antibiotics because they can treat a wide range of bacterial infections and conditions. However, using broad-spectrum antibiotics when they’re not needed can create antibiotic-resistant bacteria that are hard to treat.
This is because of the time it takes to identify the infecting pathogen with real certainty before commencing treatment. Hence, to save time, doctors administer broad-spectrum antibiotics because they can treat a wide range of bacterial infections and conditions. However, using broad-spectrum antibiotics when they’re not needed can create antibiotic-resistant bacteria that are hard to treat.
It is estimated that at least 700 000 people die every year from the infections caused by antibiotic resistant bacteria. If no action is taken the death toll may reach 10 million a year by 2050. It is more than the number of people currently dying from road traffic accidents and cancer together.
Longer stays in hospitals means increased costs for care. The World Bank anticipates that by 2050, AMR could precipitate healthcare costs to surge by up to US$ 1 trillion, with annual GDP losses ranging between US$ 1 trillion and US$ 3.4 trillion by 2030.
Resistell aims to address these challenges head-on with the fastest and most extensible AST Platform in the world. The Resistell Multistar delivers results in just 2 hours, enabling doctors to make informed decisions faster, and ensuring patients receive the most effective treatment sooner.
